Developing Clinical Trial Outsourcing Strategies that Scale As Biotechs Do
Small- to mid-size clinical trial sponsors are increasingly important drivers of innovation in the pharma and biotech industry. Given their more limited R&D resources and in-house expertise, it is especially important for them to leverage outsourcing models that enable and accelerate clinical development quickly and cost-effectively. This panel will cover best practices small-to-mid-size organizations can employ to ensure flexibility, their ability to scale and increase the value of outsourcing partnerships over time.
Brand Stewards: Creating an Omnichannel Experience for HCPs and Patients
Creating a platform to support patients and HCPs is more important than ever for brand managers. With many reps still restricted from making office visits, brand managers need to create alternative journeys to promote the company as well as individual brands.
The pharmaceutical industry’s reputation is changing for the better, driven by the industry’s innovative and heartfelt response to the pandemic. Companies have an opportunity to build on their communications strategies and step up to lead important new conversations, with the understanding that the public is actively listening in a new way.
One of the silver linings of the global pandemic has been an increase in collaboration across all stakeholders. But what comes next? Can the momentum be maintained as operations begin to normalize? Our panel of experts will discuss why multistakeholder collaboration not only raises the bar but can lead to greater productivity, increased efficiency, and better outcomes.
The importance of behavior-based decision making in early-stage development. Our focus would be on a) key considerations/questions to identify real opportunity (ie opportunity with market traction) b) key activities/analyses needed c) models for success.
Tami Klerr, Executive VP and Chief Business Development & Marketing Officer, PRA Health Sciences, 2012 Kent Thoelke, Executive Vice President and Chief Scientific Officer, PRA Health Sciences, 2013 Elizabeth Garner, MD, Chief Medical Officer, ObsEva, 2019 Jessica Scott, MD, JD, Head of R&D Patient Engagement Office, Takeda Pharmaceutical Company, 2020
Study after study shows that companies that have a strategy dedicated to aligning equity, diversity, and inclusion have better business performance, are more innovative, and have better retention numbers. But making sure this strategy is tied with a corporate mission/purpose is still not as common as it should be in the life-science industry, thought leaders discuss how companies can make smart choices and make a difference to their employee base and the industry at large.
The value to the life sciences of collaboration between the great scientific minds of pharma and the great engineering minds of the analytics industry, especially as related to the pandemic, and the potential benefits offered by a global clinical neural network that would accelerate COVID-19 therapies, as well as drugs for other diseases.
Join Jess and Dan Roomburg as they share their personal story of their daughter Mila, who lost her life due to a rare manifestation of Neurofibromatosis Type 1. The Magical Mila Foundation raises awareness about NF1 and high blood pressure in high-risk infants and toddlers. And learn how LevLane supports their efforts to raise awareness.
Did COVID change how you managed those external relationships? And could you point to a case study on how you maintained those relationships with patient groups beyond zoom meetings? In essence, was business interrupted and how did you solve the challenge?